The 20 Best Posterior Fossa Tumor Doctors Near Me in Ann Arbor, MI

Dr. Patricia Robertson, M.D., earned a medical degree at Wayne State University Medical School in Detroit and completed a residency in pediatrics at Children's Hospital of Michigan. She then went on to a fellowship in pediatric neurology at the University of Michigan and trained in pediatric neuro-oncology at New York University Medical Center. Dr. Robertson joined the University of Michigan faculty in 1988. She has a special interest in clinical pediatric neuro-oncology focusing on the evaluation of response, outcome and late effects on the developing nervous system; current treatment strategies for children with central nervous malignancies; and in the development of innovative treatment approaches for this population. Dr. Robertson is rated as a Distinguished provider by MediFind in the treatment of Posterior Fossa Tumor. She is also highly rated in 42 other conditions, according to our data. Her clinical expertise encompasses Glioma, Diencephalic Syndrome, Brain Stem Cancer, and Brain Tumor.

Dr. Wahl is a physician scientist at the University of Michigan specializing in cancers of the central nervous system. His research focuses on the development of new treatment strategies for brain tumors and his laboratory group is especially interested in interactions between radiation and abnormal metabolism in glioblastoma. In the clinic, he cares for a wide variety of patients with both malignant and benign tumors of the central nervous system. Dr. Wahl is rated as a Distinguished provider by MediFind in the treatment of Posterior Fossa Tumor. He is also highly rated in 23 other conditions, according to our data. His clinical expertise encompasses Glioblastoma, Astrocytoma, Glioma, and Brain Tumor.

Dr. Leung is the Director of the Neuro-Oncology Fellowship Program and is a clinical assistant professor in the Department of Neurology. She sees patients in the Neuro-Oncology Clinic at the Rogel Cancer Center and at the Northville Health Center. She completed a bachelor’s degree at the University of Western Ontario, a master’s degree at the University of Toronto, and medical degree at SUNY Upstate. Dr. Leung completed her Neurology residency and Neuro-Oncology fellowship at Henry Ford Hospital. Dr. Leung is rated as a Distinguished provider by MediFind in the treatment of Posterior Fossa Tumor. She is also highly rated in 26 other conditions, according to our data. Her clinical expertise encompasses Glioblastoma, Astrocytoma, Glioma, and Metastatic Brain Tumor. Dr. Leung is board certified in Neurology.

Dr. Wajd Al-Holou was raised in southeast Michigan. After attending the University of Michigan Medical School, where he graduated with the highest award for research, he then began a 7-year Neurosurgery residency at the University of Michigan. Upon completion of residency in 2016, he completed a Complex Neurosurgical Oncology Fellowship at the MD Anderson Cancer Center in Houston, TX. His training focused on the management of complex brain tumors, spinal tumors, and skull base malignancies.Dr. Al-Holou specializes in the management of complex brain tumors, primarily focusing on gliomas and metastases to the brain. Dr. Al-Holou has expertise in the use of awake mapping techniques, microsurgery, and image-guidance to maximize tumor removal in the safest possible manner. He also specializes in the management of meningiomas and spinal tumors.Dr. Al-Holou is the co-founder and co-director of the Michigan Medicine Multidisciplinary Brain Tumor Clinic (M3BTC). As a member of this Neuro-Oncology multidisciplinary team, he works strategically to ensure personalized treatment recommendations that will maximize the benefits for each individual patient.Currently, he is a member of the AANS/CNS Executive Committee of the Section on Tumors. He served as the Co-Chair for Tumor Section Scientific Program for the American Association of Neurological Surgeons (AANS) in 2018 and is a member of the Society of Neuro-Oncology. He also serves as an editor for cancer journal, BMC Cancer.Dr. Al-Holou is committed to research and education in Neurosurgery and his life-long goal is improving the survival and outcomes for patients with tumors. His research interest focuses primarily on understanding the genetic mechanisms of recurrence in glioblastoma, and in identifying precision medicine therapies to target resistant tumors. Dr. Al is rated as a Distinguished provider by MediFind in the treatment of Posterior Fossa Tumor. He is also highly rated in 26 other conditions, according to our data. His clinical expertise encompasses Primitive Neuroectodermal Tumor (PNET), Posterior Fossa Tumor, Astrocytoma, Oligodendroglioma, and Awake Craniotomy. Dr. Al is board certified in Neurological Surgery.

Dr. Jason Heth attended The University of Iowa where he received his medical degree and also completed his residency in Neurosurgery. Dr. Heth then completed additional training in Skull Base Neurosurgery, completing a fellowship at the University of Arkansas for Medical Sciences. After completing his fellowship, he joined the faculty of the University of Michigan. Dr. Heth specializes in brain tumor treatment, including surgical removal, radiosurgery, and basic research. His primary areas of interest focus on gliomas, glioblastoma, brain metastasis, and meningiomas. He is also involved in medical student education and quality improvement programs at the University of Michigan. Dr. Heth is rated as a Distinguished provider by MediFind in the treatment of Posterior Fossa Tumor. He is also highly rated in 33 other conditions, according to our data. His clinical expertise encompasses Glioblastoma, Astrocytoma, Brain Tumor, Awake Craniotomy, and Gastrostomy. Dr. Heth is board certified in Neurological Surgery.

Michelle Kim, M.D. is an associate professor in the Department of Radiation Oncology at the University of Michigan. She completed her medical training at Case Western Reserve University and her residency at MD Anderson Cancer Center. Dr. Kim is board-certified in Radiation Oncology by the American Board of Radiology. Her research focus is in the adaptive individualization of radiation therapy using advanced molecular and functional imaging for patients with central nervous system tumors including gliomas and brain metastases. Dr. Kim is rated as a Distinguished provider by MediFind in the treatment of Posterior Fossa Tumor. She is also highly rated in 30 other conditions, according to our data. Her clinical expertise encompasses Posterior Fossa Tumor, Primitive Neuroectodermal Tumor (PNET), Metastatic Brain Tumor, and Astrocytoma. Dr. Kim is board certified in Radiation Oncology.

Dr. James Hayman received his medical and master of business administration degrees simultaneously from the University of Chicago in 1991. Following an internship in Evanston, Ill., he began his radiation oncology residency at the Joint Center for Radiation Therapy at Harvard Medical School. He joined the University of Michigan faculty immediately following his residency in 1996 and currently serves as the director of the Clinical Division of the Department of Radiation Oncology. Dr. Hayman's clinical interests include the management of lung, esophageal, breast and central nervous system malignancies. He is also active in the area of health services research. Dr. Hayman is rated as a Distinguished provider by MediFind in the treatment of Posterior Fossa Tumor. He is also highly rated in 24 other conditions, according to our data. His clinical expertise encompasses Lung Cancer, Melanoma of the Eye, Merkel Cell Carcinoma, and Small Cell Lung Cancer (SCLC). Dr. Hayman is board certified in Radiation Oncology and Hospice & Palliative Med.

Dr. Kalemkerian completed his medical education and training at Northwestern University and Johns Hopkins Oncology Center. From 1993-1999, he was a physician-scientist at Wayne State University/Karmanos Cancer Institute in Detroit. Since 1999, he has been on faculty in the Division of Hematology/Oncology at the University of Michigan, where he currently serves as the Associate Division Chief for Faculty Development and Education and the Associate Director of the Hem/Onc Fellowship Program. In addition to his work at UM, Dr. Kalemkerian has served on and led numerous grant review sections, editorial boards, and committees of national and international professional societies. He is a former chair of the NCCN Small Cell Lung Cancer Guideline Panel and the ASCO Scientific Program Committee’s Metastatic NSCLC and Professional Development and Education Tracks. Dr. Kalemkerian’s clinical interest is the care of people with lung cancer, thymic tumors, and mesothelioma, and his academic research interest is clinical and translational trials for thoracic cancers. His honors include the receipt of the American Society of Clinical Oncology’s (ASCO) Excellence in Teaching Award, the University of Michigan Outstanding Clinician Award, and Fellow of ASCO recognition. He has given over 230 invited lectures, authored more than 200 research articles, reviews, commentaries and book chapters, and edited two books on lung cancer. Dr. Kalemkerian is rated as a Distinguished provider by MediFind in the treatment of Posterior Fossa Tumor. He is also highly rated in 16 other conditions, according to our data. His clinical expertise encompasses Small Cell Lung Cancer (SCLC), Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), and Lung Adenocarcinoma. Dr. Kalemkerian is board certified in Internal Medicine and Medical Oncology.

Larry Junck is a Neurologist practicing medicine in Ann Arbor, Michigan. Dr. Junck is rated as a Distinguished provider by MediFind in the treatment of Posterior Fossa Tumor. He is also highly rated in 18 other conditions, according to our data. His clinical expertise encompasses Astrocytoma, Glioblastoma, Glioma, and Brain Tumor.

Dr. Mihaylova was born and raised in Bulgaria where she completed Medical School at the University of Sofia in 1997. Subsequently she extended her training into a three-year post-doctoral program and conducted clinical research on newly diagnosed epilepsy patients. She was granted her PhD degree in 2002. Since then she has been living in the US where she completed her Neurology residency at Wayne State University followed by a year of fellowship training in Clinical Neurophysiology with emphasis on Epilepsy/EEG at the same institution. Her primary clinical and research interests involve the treatment of medically intractable epilepsy including VNS and surgical treatment, EEG analysis and seizure semiology. Dr. Mihaylova is rated as an Experienced provider by MediFind in the treatment of Posterior Fossa Tumor. She is also highly rated in 24 other conditions, according to our data. Her clinical expertise encompasses Seizures, Autosomal Dominant Nocturnal Frontal Lobe Epilepsy (ADNFLE), Generalized Tonic-Clonic Seizure, and Partial Seizure. Dr. Mihaylova is board certified in Neurology, Clinical Neurophysiology, and Epilepsy.

Eva Bieniek is a Radiation Oncologist practicing medicine in Ypsilanti, Michigan. Dr. Bieniek is rated as a Distinguished provider by MediFind in the treatment of Posterior Fossa Tumor. She is also highly rated in 12 other conditions, according to our data. Her clinical expertise encompasses Posterior Fossa Tumor, Lung Cancer, Pleuropulmonary Blastoma, and Endometrial Cancer.

Richard Cattaneo is a Radiation Oncologist practicing medicine in Ypsilanti, Michigan. Dr. Cattaneo is rated as a Distinguished provider by MediFind in the treatment of Posterior Fossa Tumor. He is also highly rated in 16 other conditions, according to our data. His clinical expertise encompasses Pleuropulmonary Blastoma, Lung Cancer, Posterior Fossa Tumor, and Primitive Neuroectodermal Tumor (PNET).

Terri Bott-Kothari, MD has been in practice for over 16 years treating all disease sites. She completed her medical training at Wayne State University School of Medicine and residency at the University of Cincinnati. Dr. Bott is rated as an Advanced provider by MediFind in the treatment of Posterior Fossa Tumor. She is also highly rated in 6 other conditions, according to our data. Her clinical expertise encompasses Pleuropulmonary Blastoma, Posterior Fossa Tumor, Primitive Neuroectodermal Tumor (PNET), and Familial Prostate Cancer. Dr. Bott is board certified in Radiation Oncology.

Hugh Garton is a Neurosurgery provider practicing medicine in Ann Arbor, Michigan. Dr. Garton is rated as an Advanced provider by MediFind in the treatment of Posterior Fossa Tumor. He is also highly rated in 72 other conditions, according to our data. His clinical expertise encompasses Chiari Malformation, Chiari Malformation Type 1, Chiari Malformation Type 2, Posterior Fossa Decompression, and Gamma Knife Radiosurgery. Dr. Garton is board certified in Neurological Surgery.

Neena Marupudi is a Neurosurgery provider practicing medicine in Ann Arbor, Michigan. Dr. Marupudi is rated as an Advanced provider by MediFind in the treatment of Posterior Fossa Tumor. She is also highly rated in 53 other conditions, according to our data. Her clinical expertise encompasses Hydrocephalus, Tethered Cord Syndrome, Chiari Malformation Type 1, Rhizotomy, and Laminectomy. Dr. Marupudi is board certified in Neurological Surgery.

Dr. Magge is a Clinical Professor of Neurosurgery and serves as the Surgical Director of the Pediatric Brain Tumor Program. His clinical practice encompasses all types of pediatric neurosurgery, with particular clinical and research interests in pediatric brain tumors, craniosynostosis (endoscopic and open surgery), and pediatric neurovascular disease (including AVM’s and moyamoya disease). His brain tumor research has focused on finding better treatments for diffuse intrinsic pontine gliomas (DIPG’s) and methods for liquid biopsy. He has been involved in multicenter clinical trials. In the field of craniosynostosis, he has been the principal investigator of a multicenter trial examining long term outcomes of children with craniosynostosis treated with either endoscopic or open surgery. He also started the first endoscopic craniosynostosis surgery program in the Washington, DC area and helped to grow a busy craniosynostosis practice in California. He has authored numerous scholarly papers, and he is a regular speaker at national and international conferences. Dr. Magge works to find the best treatment for each patient in the least invasive method possible.Prior to joining University of Michigan Health, Dr. Magge served as the Director of Neurosurgery and Co-Director of the Children’s Hospital of Orange County Neuroscience Institute and Professor of Clinical Neurosurgery at University of California Irvine. Prior to that, he was a faculty member in the Division of Pediatric Neurosurgery at Children’s National Hospital in Washington, DC, where he started the pediatric neurosurgery fellowship program and served as fellowship director.Dr. Magge grew up in Cincinnati, Ohio, and he attended Harvard College for his undergraduate studies, where he majored in biochemistry. He then obtained his medical degree from Harvard Medical School, graduating in 2001. During medical school, he completed a 1 year Howard Hughes research fellowship at the NIH. He then completed neurosurgery residency training at the University of Pennsylvania in 2008, and fellowship training in pediatric neurosurgery at Boston Children’s Hospital in 2009. Dr. Magge is rated as an Advanced provider by MediFind in the treatment of Posterior Fossa Tumor. He is also highly rated in 42 other conditions, according to our data. His clinical expertise encompasses Craniosynostosis, Plagiocephaly, Cortical Dysplasia, Craniectomy, and Posterior Fossa Decompression. Dr. Magge is board certified in Neurological Surgery and Pediatric Neurosurgery.

David Altshuler is a Neurosurgery provider practicing medicine in Ann Arbor, Michigan. Dr. Altshuler is rated as an Advanced provider by MediFind in the treatment of Posterior Fossa Tumor. He is also highly rated in 48 other conditions, according to our data. His clinical expertise encompasses Pituitary Tumor, Rathke Cleft Cyst, Craniopharyngioma, Awake Craniotomy, and Extracranial-Intracranial Bypass Surgery.

Dr. Lawrence structured his career to prepare to be a physician scientist by obtaining both an MD and PhD. He initially pursued internal medicine and medical oncology, but ultimately settled on radiation oncology. He is board certified in all 3 areas. He has had an active clinical practice in radiation oncology for 30 years specializing in the treatment of patients with gastrointestinal malignancies and CNS tumors.Dr. Lawrence has focused his research career in two main areas. First, in collaboration with basic scientists he developed a laboratory program in chemotherapeutic radiation sensitizers and, more recently, has studied how to integrate molecularly targeted therapies. He collaborates with basic science faculty interested in translational research to investigate new combinations that can form the basis for rational clinical trials. The second area of focus involves the use of highly conformal radiation therapy in the treatment of brain and gastrointestinal cancers. In particular, he is focusing, in collaboration with medical physicists, radiologists, imaging scientists, and biologists, on the concept of adapting treatment to the individual patient response, assessed both by state-of-the-art imaging and plasma biomarkers.Dr. Lawrence is the author of over 300 peer-reviewed publications, and his work has been continuously supported by the National Cancer Institute for over 20 years. Dr. Lawrence is rated as an Advanced provider by MediFind in the treatment of Posterior Fossa Tumor. He is also highly rated in 24 other conditions, according to our data. His clinical expertise encompasses Glioma, Glioblastoma, Astrocytoma, Pancreaticoduodenectomy, and Tissue Biopsy. Dr. Lawrence is board certified in Radiation Oncology, Medical Oncology, and Internal Medicine.

Nathan Clarke is a Neurologist practicing medicine in Ann Arbor, Michigan. He has been practicing medicine for over 10 years. Dr. Clarke is rated as an Advanced provider by MediFind in the treatment of Posterior Fossa Tumor. He is also highly rated in 26 other conditions, according to our data. His clinical expertise encompasses Glioma, Astrocytoma, Brain Tumor, and Glioblastoma. Dr. Clarke is board certified in Neurology.

Bryan J. Schneider, MD is a Professor of Internal Medicine in the Division of Hematology/ Oncology at the University of Michigan, Ann Arbor, Michigan, and is the Section Head for the medical thoracic oncology team who treats lung cancer, esophageal cancer, mesothelioma, thymoma and carcinoid tumors.Dr. Schneider earned his medical degree from Indiana University in 1998. He also completed an internship and residency in internal medicine at the Indiana University School of Medicine and served as Chief Resident in 2001. He completed a fellowship in hematology/oncology at the University of Michigan. He joined the faculty at the University of Michigan as an Assistant Professor in 2005 and was an Assistant Professor at Cornell University in New York City from 2008 to 2014. He returned to the University of Michigan in 2015.Dr. Schneider is a member of the American Society of Clinical Oncology and the International Association for the Study of Lung Cancer. He has served as a member of the Experimental Therapeutics Study Section of the National Institutes of Health and serves on numerous other scientific medical committees. These include the ASCO thoracic guideline advisory group, and the steering committee for the National Cancer Center Network (NCCN) guidelines.Dr. Schneider has published extensively in peer-reviewed journals and has written several book chapters on the subject of lung cancer. He is married with twin boys and a cat. Dr. Schneider is rated as an Advanced provider by MediFind in the treatment of Posterior Fossa Tumor. He is also highly rated in 15 other conditions, according to our data. His clinical expertise encompasses Small Cell Lung Cancer (SCLC), Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Lung Adenocarcinoma, and Tissue Biopsy. Dr. Schneider is board certified in Medical Oncology.